Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial

Stock Information for Achieve Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.